Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Fed In ‘Pro-Growth Mode’ Will Drive Small Cap Performance, Lazard Expert Says – iShares Russell 2000 ETF (ARCA:IWM)
    Small caps

    Fed In ‘Pro-Growth Mode’ Will Drive Small Cap Performance, Lazard Expert Says – iShares Russell 2000 ETF (ARCA:IWM)

    userBy userSeptember 19, 2024No Comments3 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    A Federal Reserve focused on supporting the economy through rate cuts is a robust bullish catalyst for U.S. small-cap stocks, according to Sean Gallagher, global head of Lazard’s small-cap equity platform.

    In an exclusive interview with Benzinga, Gallagher reaffirmed his strong optimism that small caps will close the performance gap with large caps that has widened in recent years.

    “The Fed is in ‘pro-growth mode,’ and easing financial conditions are very helpful for many parts of the economy,” he stated.

    “I think laggard areas like small caps are a lot more attractive.” While Gallagher noted that the broader market isn’t cheap—given that the S&P 500 trades at over 20 times its earnings—small caps remain comparatively undervalued, trading at half the S&P 500’s price-to-earnings ratio.

    Following the Fed’s bold decision to slash rates by 50 basis points to 4.75-5%, the Russell 2000, as tracked by the iShares Russell 2000 ETF IWM, had a volatile reaction on Wednesday, closing flat for the day.

    Yet, as investors digest the decision, small caps rose by 1.7% on Thursday, outperforming larger-cap counterparts.

    Don’t miss out on this unparalleled opportunity:

    Gallagher reiterated his call of “at least 30% upside on a 12 month basis,” for the Russell 2000.

    “There’s no question” that even the group of non-earners within the small-cap index could benefit significantly from aggressive rate cuts, such as the 50 basis point reduction, he added.

    As we enter what he describes as “a pretty aggressive rate-cutting cycle,” the market could expand beyond the heavily concentrated Magnificent Seven, bringing small caps into focus for retail investors.

    The expert maintains a constructive outlook on the economy, dismissing fears of a slowdown. While he acknowledges some labor market softness, he doesn’t view it as a sign of fundamental weakness.

    Fed To Cut By 25Bps At Every Meeting

    Gallagher anticipates 25 basis point rate cuts at each upcoming Fed meeting. “We’re in a much better place with inflation and are gradually getting back to trend,” he said.

    He foresees a steady series of 25 basis point cuts following the initial front-loaded 50 basis point cut.

    “I think we’re in a ‘good is good and bad is bad’ kind of mindset going forward,” Gallagher said. Positive economic data will benefit the markets, whereas negative data, particularly on the labor market front, may disappoint investors.

    Small Caps Poised To Play Catch-Up, Biotech In Focus

    Gallagher believes cyclical sectors are set to rise here.

    He is particularly optimistic about companies with lean inventories, solid balance sheets, and free cash flow, especially those enduring the current tough cycle. “When demand comes back, you’ll see meaningful appreciation,” he said.

    Gallagher also sees potential in the biotech sector, noting that higher rates have been restrainting funding for years.

    “We’re definitely active in healthcare, looking for opportunities with companies that have diversified pipelines, solid balance sheets, and are poised to benefit when biotech funding picks up,” he added.

    Don’t miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10, 2024, at the Chicago Marriott Downtown Magnificent Mile.

    Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you’re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders.

    Secure your spot and get your tickets today!

    Read Next:

    Photo: Shutterstock

    © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleAI told me how to sue you, serial job applicant told business
    Next Article Trump’s crypto allies boast lavish lifestyles amid trail of debts
    user
    • Website

    Related Posts

    BioVaxys Advances DPX™ as mRNA Vaccine Carrier Amid USD $48B Market Growth

    January 15, 2025

    Givbux Inc UPLIST TO BE FULLY REPORTING

    January 7, 2025

    BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

    December 17, 2024
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d